Idarucizumab (Praxbind®) – studie RE-VERSE AD
| Title in English | Idarucizumab (Praxbind®) – the RE-VERSE AD study |
|---|---|
| Authors | |
| Year of publication | 2016 |
| Type | Article in Periodical |
| Magazine / Source | Hypertenze & kardiovaskulární prevence |
| MU Faculty or unit | |
| Citation | |
| Field | Oncology and hematology |
| Keywords | thrombin; inhibitor; antidote; idarucizumab; RE-VERSE AD |
| Description | The recent introduction of idarucizumab as specific antidote for dabigatran to clinical practice represents an important progress in safety of antithrombotic therapy. The RE-VERSE AD study confirmed the efficacy and safety of idarucizumab for dabigatran reversal. |